Greenman Christopher, Stephens Philip, Smith Raffaella, Dalgliesh Gillian L, Hunter Christopher, Bignell Graham, Davies Helen, Teague Jon, Butler Adam, Stevens Claire, Edkins Sarah, O'Meara Sarah, Vastrik Imre, Schmidt Esther E, Avis Tim, Barthorpe Syd, Bhamra Gurpreet, Buck Gemma, Choudhury Bhudipa, Clements Jody, Cole Jennifer, Dicks Ed, Forbes Simon, Gray Kris, Halliday Kelly, Harrison Rachel, Hills Katy, Hinton Jon, Jenkinson Andy, Jones David, Menzies Andy, Mironenko Tatiana, Perry Janet, Raine Keiran, Richardson Dave, Shepherd Rebecca, Small Alexandra, Tofts Calli, Varian Jennifer, Webb Tony, West Sofie, Widaa Sara, Yates Andy, Cahill Daniel P, Louis David N, Goldstraw Peter, Nicholson Andrew G, Brasseur Francis, Looijenga Leendert, Weber Barbara L, Chiew Yoke-Eng, DeFazio Anna, Greaves Mel F, Green Anthony R, Campbell Peter, Birney Ewan, Easton Douglas F, Chenevix-Trench Georgia, Tan Min-Han, Khoo Sok Kean, Teh Bin Tean, Yuen Siu Tsan, Leung Suet Yi, Wooster Richard, Futreal P Andrew, Stratton Michael R
Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Nature. 2007 Mar 8;446(7132):153-8. doi: 10.1038/nature05610.
Cancers arise owing to mutations in a subset of genes that confer growth advantage. The availability of the human genome sequence led us to propose that systematic resequencing of cancer genomes for mutations would lead to the discovery of many additional cancer genes. Here we report more than 1,000 somatic mutations found in 274 megabases (Mb) of DNA corresponding to the coding exons of 518 protein kinase genes in 210 diverse human cancers. There was substantial variation in the number and pattern of mutations in individual cancers reflecting different exposures, DNA repair defects and cellular origins. Most somatic mutations are likely to be 'passengers' that do not contribute to oncogenesis. However, there was evidence for 'driver' mutations contributing to the development of the cancers studied in approximately 120 genes. Systematic sequencing of cancer genomes therefore reveals the evolutionary diversity of cancers and implicates a larger repertoire of cancer genes than previously anticipated.
癌症是由于赋予生长优势的一组基因发生突变而产生的。人类基因组序列的可得性促使我们提出,对癌症基因组进行系统的重测序以寻找突变将导致发现许多其他癌症基因。在此,我们报告了在210种不同人类癌症中,对应于518个蛋白激酶基因编码外显子的2.74亿碱基对(Mb)DNA中发现的1000多个体细胞突变。个体癌症中突变的数量和模式存在很大差异,这反映了不同的暴露情况、DNA修复缺陷和细胞起源。大多数体细胞突变可能是对肿瘤发生没有贡献的“乘客”突变。然而,有证据表明约120个基因中的“驱动”突变促成了所研究癌症的发展。因此,癌症基因组的系统测序揭示了癌症的进化多样性,并暗示了比以前预期更多的癌症基因库。